Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Jack Khattar In concluding our call this afternoon, we're very pleased with our performance in 2023 |
| I think we've been able to really manage it extremely well |
| Specifically, our growth products, Qelbree and GOCOVRI delivered robust 57% growth in combined net sales compared to last year |
| So that's a very healthy increase and improvement, clearly with the value of a prescription, and we'll continue to do that throughout 2024 |
| And third, advancing our innovative R&D portfolio of differentiated first-in-class molecules that have several exciting and upcoming clinical milestones |
| Net sales for 2023 recorded an even stronger growth rate of 129%, benefiting from the prescription growth and the steady improvement in gross to net throughout the year |
| Moreover, Qelbree finished the year with a strong fourth quarter, reaching net sales of $46.4 million, that represents a 97% increase over the growth quarter -- of the fourth quarter of 2022 and a 25% sequential quarter-to-quarter increase from the third quarter of 2023 |
| From a net sales perspective, we had a very, very strong quarter, despite the pressure on the prescriptions |
| First, driving significant growth with Qelbree and GOCOVRI and together with the rest of the portfolio, generating strong cash flow, allowing us to continue our investments in our pipeline |
| Excluding Trokendi XR, Supernus delivered strong growth of 26% in total revenues in 2023, compared to 2022 |
| The team done an amazing job in the fourth quarter, despite the pressures on the prescriptions and so forth |
| And within the states, we continue to renew contracts, improve our position as time goes on |
| We continue to be pleased with the performance of the brand based on its unique position in the marketplace, treating both off episodes and dyskinesia |
| Our performance in 2023 underscored our strong execution and emphasis on growing our revenue base despite the loss of exclusivity on Trokendi XR |
| So we're very happy that this is behind us |
| We finished the year in a position of strength with both Qelbree and GOCOVRI, achieving record sales with strong prescription growth |
| Now, as far as prescription in the underlying business, I mean, we continue to really be very happy with the performance of Qelbree |
| And for Qelbree to be performing around that same level and to deliver a satisfaction among prescribers that is really equivalent to XR stimulants, that is pretty remarkable for the product and continues to give us confidence that the product will continue to grow |
| So all in all, we're very much looking forward to another strong year for Qelbree in 2024 |
| The company has a strong balance sheet and significant financial flexibility for potential M&A and other value-creating opportunities |
| And then it will improve in the second quarter, improve a little bit better in the third quarter, and then will be the best one in the fourth quarter |
| So we're very happy there |
| We continue to be encouraged by the high level of satisfaction by Qelbree's prescribers |
| We believe that we are well-positioned for continued growth beyond the current transition and are focused on three key strategic areas |
| If you really pause for a second and think about that, I mean, that is truly remarkable for a non-stimulant to be delivering and really performing in physicians' minds, as well as extended-release stimulants |
| In addition, combined full year 2023 net sales for Qelbree and GOCOVRI reached approximately $260 million, which significantly exceeded the $167 million decline in net sales of Trokendi XR |
| And that's why actually we've been able to achieve our goal or even surpass that goal by getting around 49.5% gross to net on Qelbree |
| In addition, as mentioned earlier, 2023 was a year of significant progress on our pipeline with numerous clinical milestones and catalysts over the next 12 months to 18 months |
| It looks like that is really good, 40% |
| We also have different influencers who are -- as well spokespeople who speak on behalf of the product because they had direct experience with the product and they have a strong influence among consumers as well |
| Statement |
|---|
| For Trokendi XR, full year net sales were $94 million, down by 64% from the $261 million in 2022 |
| So Q1 will always be the worst, as always is the case across our industry, across all products |
| This non-cash charge reflects the forthcoming loss of exclusivity of XADAGO in December of 2027 |
| So looking at the prescription trends recently and also in the fourth quarter, it looks a little softer than what we had been seeing |
| In 2024, we don't expect an increase in the number of generic players in the market, but expect further erosion in Trokendi XR sales |
| And that's why you're seeing the softness that we're all looking at with the prescriptions |
| So all these factors are converging as far as 1Q is concerned |
| And then in 1Q of 2024, it is a little bit even softer, because of course, in 1Q, you always have the additional pressures of high deductibles, insurance resets, and so forth |
| The $7.8 million decrease in net product sales was primarily due to a $37.6 million decline in net product sales of Trokendi XR, partially offset by a $25.6 million increase in net product sales of our growth products, Qelbree and GOCOVRI |
| In addition to the items above, full year 2023 include the aforementioned non-cash impairment charge of $20.2 million, resulting in an operating loss for full year 2023 of $5.3 million, as compared to operating earnings of $46.1 million for the prior year |
| The $75.5 million decrease in net product sales was primarily due to $166.9 million decline in net product sales of Trokendi XR, partially offset by a $94.1 million increase in net product sales of our growth products, Qelbree and GOCOVRI |
| As a result of the impairment charge, operating loss for the fourth quarter of 2023 was approximately $1 million, as compared to operating earnings of $34.3 million for the same period in 2022 |
| So kind of on the topic of the previous quarter's call, I know you had mentioned that the start of the 2023 back-to-school season was relatively tempered and the ADHD market might be normalizing to pre-COVID levels |
| Now clearly that always comes at the cost or sacrificing certain things on the prescription trends |
| Overall, we expect full year 2024 operating loss in the range of $30 million to break even |
Please consider a small donation if you think this website provides you with relevant information